Toripalimab With Preoperative Chemoradiotherapy for LA-EGJ

• Status: Not yet recruiting
• Trial end date: 2023-08-25
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to investigate the safety and efficacy of radiotherapy combined with Toripalimab (PD-1 inhibitor) in the treatment of locally advanced adenocarcinoma of the gastroesophageal junction.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Peking University

Criteria

Inclusion Criteria:

• 1) Age 18-75, male and female.

2) ECOG score was 0-1.

3) Diagnosis of adenocarcinoma in the gastroesophageal junction.

4) Initial treatment of locally advanced patients (cT3-4 or N+, and M0).

5) The estimated survival time will be more than 12 months.

6) Adequate organ reserve function.

7) agree to join the group, willing to cooperate with clinical research, and sign the informed consent.

Exclusion Criteria:

• 1) Patients have received immunotherapy, such as PD-1 antibody, PD-L1 antibody and CTLA4 antibody.

2) Immunosuppressive drugs were used within 4 weeks before admission.

3) Active infection, acute myocardial infarction in recent 6 months, severe arrhythmia requiring long-term drug intervention, severe stroke, uncontrolled epilepsy or other serious medical complications.

4) In the past five years, there have been other malignant diseases except for cured skin cancer and cervical cancer in situ.